Floatz logo

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS

Pancreatic Neoplasm

ImmunityBio, Inc.Cell therapyPhase 1/2Dormant
D
26/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
59/ 100

Competitive context

382 Active assets in the Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

HUMAN NATURAL KILLER CELL LINE NK-92 (CD16.158V, ER IL2) CELLS is also rated in:

triple-negative breast carcinomaDormant
C
Indicative ·
37 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →